Results 1 to 10 of about 32,890 (266)

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease [PDF]

New England Journal of Medicine, 2016
BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease.
Yinghua Lang, Joshua R Friedman, Omoniyi J Adedokun   +2 more
exaly   +5 more sources

Ustekinumab [PDF]

Nature Reviews Drug Discovery, 2009
Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis.In large clinical trials, ustekinumab has proven effective
Kristian Reich
exaly   +5 more sources

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine, 2019
BACKGROUND The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.
Bruce E Sands, Remo Panaccione, Omoniyi J Adedokun   +2 more
exaly   +2 more sources

Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS) [PDF]

Rheumatology and Therapy
Introduction The “Ustekinumab Pediatric Opportunistic Pharmacokinetics Study” (U-POPS) was conducted to evaluate the pharmacokinetics (PK) and safety of ustekinumab, an interleukin-12/23p40 antagonist, in patients with juvenile psoriatic arthritis (jPsA)
Edwin Lam, Katherine Berezny, Corey J. Bishop, Kathleen G. Lomax, Sophia G. Liva, Hermine I. Brunner, Amy S. Paller, Lucia Z. Diaz, Lara Wine Lee, Cory Rubin, Ruy Carrasco, Lisa Imundo, Azadeh Majlessi, Valerie Smith, Renping Zhang, Jocelyn H. Leu, the U-POPS Study Group   +16 more
doaj   +2 more sources

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Ustekinumab and vedolizumab are both effective for treating Crohn’s disease (CD). However, no head-to-head trials have been conducted thus far.
Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao   +19 more
doaj   +2 more sources

Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial

Nature Medicine
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D.
Megan K Levings, Emily Pollock, Jennie H M Yang   +2 more
exaly   +2 more sources

Toward personalized therapeutic drug monitoring of ustekinumab in Crohn’s disease: influence of previous exposure to biologics [PDF]

Therapeutic Advances in Gastroenterology
Background: Unlike infliximab, ustekinumab (UST) has shown inconsistent associations between drug concentration and clinical efficacy across studies, with varying cutoff therapeutic trough levels (TLs) proposed.
Yiyoung Kwon, Yoon Zi Kim, Tae Jong Jeong, Seon Young Kim, Hansol Kim, Eun Sil Kim, Yon Ho Choe, Mi Jin Kim   +7 more
doaj   +2 more sources

Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review

Frontiers in Medicine, 2023
Ustekinumab is a biological therapy that has been approved for treating moderate-to-severe psoriasis. Although injection site reactions, nasopharyngitis, headaches, and infections are the common adverse events associated with ustekinumab, the development
Luyang Kong, Luyang Kong, Dawei Huang, Dawei Huang, Jiajing Lu, Jiajing Lu, Yuexin Zhang, Yuexin Zhang, Ying Li, Ying Li, Xuemei Yi, Xuemei Yi, Yuling Shi, Yuling Shi   +13 more
doaj   +1 more source

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis

Frontiers in Medicine, 2022
IntroductionThere is growing evidence that therapeutic drug monitoring of biologic therapy is beneficial in psoriatic patients. With respect to ustekinumab, the available evidence has not shown any relationship yet.
Laida Elberdín, Rosa M. Fernández-Torres, María Mateos, María Outeda, Eva Blanco, María I. Gómez-Besteiro, Isabel Martín-Herranz, Eduardo Fonseca   +7 more
doaj   +1 more source

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Medical Mycology Case Reports, 2021
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab.
Yun-Han Huang, Reed Magleby, Rema Rao, Thomas J. Walsh, Harjot K. Singh   +4 more
doaj   +1 more source